Origins and pathogenesis of Autoimmune and Inflammatory disorders
The aim of our group is to better understand the origination and development of autoimmune and autoinflammatory disorders (AID). Using observational studies in patient cohorts along with in vitro and in vivo experiences in the lab, we strive to better understand the functional specificities behind these diseases in order to improve diagnosis and treatment options for patients.
The term autoimmune and autoinflammatory disorders (AID) encompasses a large number of conditions that have in common a dysregulation of the immune system. Most AIDs are chronic diseases for which a cure does not yet exist, but their progression can be slowed down. Therefore our team works on two complementary strategies: Identifying markers for the earliest stages of the disease, in order to delay their evolution as much as possible, and characterize the underlying mechanisms of the disease, to open up new therapeutic avenues.
The members of our group have expertise in different AIDs such as lupus, systemic sclerosis, vitiligo and multiple sclerosis. Collectively they have long standing experience in fundamental, translational and clinical research. The group is organized in 5 researches axes:
• T-cell dependent B-cell activation in the model of Lupus.
• Inflammation and fibrosis in human pathophysiology
• Crosstalk between immune and epidermal cells
• DNA sensing
• Gut derived T-cells
The different axes each use their own disease model and together they present an in depth analysis of the immune system and its possible malfunctions.
T cell-dependent B cell activation in the model of Lupus
Inflammation and fibrosis in human pathophysiology
Crosstalk between immune and epidermal cells
Gut-derived T cells
Mitochondrial biology and innate immunity
- Guerville, F, Vialemaringe, M, Cognet, C, Duffau, P, Lazaro, E, Cazanave, C et al.. Mechanisms of systemic low-grade inflammation in HIV patients on long-term suppressive antiretroviral therapy: the inflammasome hypothesis. AIDS. 2023;37 (7):1035-1046. doi: 10.1097/QAD.0000000000003546. PubMed PMID:36928274 .
- Silverberg, JI, Guttman-Yassky, E, Thaçi, D, Irvine, AD, Stein Gold, L, Blauvelt, A et al.. Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis. N Engl J Med. 2023;388 (12):1080-1091. doi: 10.1056/NEJMoa2206714. PubMed PMID:36920778 .
- Rosmarin, D, Passeron, T, Pandya, AG, Grimes, P, Harris, JE, Desai, SR et al.. Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo. N Engl J Med. 2022;387 (16):1445-1455. doi: 10.1056/NEJMoa2118828. PubMed PMID:36260792 .
- Izadi, Z, Gianfrancesco, MA, Schmajuk, G, Jacobsohn, L, Katz, P, Rush, S et al.. Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study. Lancet Rheumatol. 2022;4 (9):e603-e613. doi: 10.1016/S2665-9913(22)00192-8. PubMed PMID:35909441 PubMed Central PMC9313519.
- Blaye, C, Darbo, É, Debled, M, Brouste, V, Vélasco, V, Pinard, C et al.. An immunological signature to predict outcome in patients with triple-negative breast cancer with residual disease after neoadjuvant chemotherapy. ESMO Open. 2022;7 (4):100502. doi: 10.1016/j.esmoop.2022.100502. PubMed PMID:35759853 PubMed Central PMC9434232.
- Seneschal, J, Boniface, K, Jacquemin, C. Alopecia areata: Recent advances and emerging therapies. Ann Dermatol Venereol. 2022;149 (4):222-227. doi: 10.1016/j.annder.2022.03.006. PubMed PMID:35752494 .